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if the primary indication was claudication. Bowel obstruction,
fistula, and incisional hernia are also not long-term complications.
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DrMarkR.Nehler (Aurora, Colo). Dr Danczyk and colleagues
from Oregon Health & Science University present a comparison
series of either multiple vs isolated endovascular treatment with stents
in the iliac system. The procedural indications, demographics, and
comorbidities are typical of the predominately Veterans Affairs popu-
lation it represents. Of note, roughly 20% to 30% of the patients were
not on either statins or antiplatelet therapy at the time of procedure,
reflecting the 12-year time frame of the data set; both medications
would be required as background therapy in clinical trials currently.
Failure to cross the lesions was not included, making the results a bit
better than reality and the loss to follow-up was high, at 20%, also
reflecting the long duration of the study period.
Regardless of these study limitations, several points are
undeniable: 15 to 25 percentage points of the lesions treated
were TransAtlantic Inter-Society Consensus (TASC) D—more
so in the multiple iliac stent group. There was no difference in
the multiple vs isolated iliac stent group in secondary interven-
tion and salvage operation over time, both a modest 15% and
8%, respectively. As such, this paper joins others that have
demonstrated that a large number of TASC D iliac lesions can
be treated successfully with an endovascular-first approach.
The TASC II guidelines were roundly criticized for the inclu-
sion of many lesions in the C and D classes that could be ap-
proached endovascularly. Such is the risk of putting out lesion
classification systems in a decade of such rapid improvements in
endovascular techniques and widespread adoption of same. A
proposed revised lesion scoring system would adjust all the lesions
(aortoiliac, femoropopliteal, and a new tibial system) toward the
endovascular side of the ledger, with only a few anatomic cases
suggested as primary open surgery, with the vast majority of open
revascularization to follow endovascular failure. This proposal has
yet to be approved by all societies, as the actual data below the
inguinal ligament is not as strong as in the iliacs.
As such the TASC lesion system is really most beneficial as a
tool to compare anatomic arterial substrate and really corresponds
to the T portion of the TNM classification system in oncology. It
allows comparisons in registries, clinical trials, etc. Since the orig-
inal system commented on open vs endovascular success likeli-
hood, it has required revision over time as endovascular techniques
and tools improved – and also the lesion classification has been
contentious for the implications for clinical practice, which is really
not the intent of the system per se.
As time goes by, many of the classic teaching regarding the
limitations of endovascular approaches in the iliacs are fading.
There are secondary procedures, but the actual number is not
huge. There is device cost, but shorter hospital stays account for
that, and it is cost-effective. Indeed, with the current bed crunch in
most hospitals and patients in the emergency department waiting
for beds, adding to the inpatient load with more open aortic
procedures is hardly feasible.
The failure of iliac endovascular approaches also appears more
favorable than open surgery. Infection is a rare event. As opposed
to a graft limb occlusion, a failure of endovascular therapy in the
iliacs appears less likely to embolize and lead to acute limb ischemiaenjoyed the paper. It is well written and the analysis is very clear.
o close, I have several questions for the authors:
First, my personal observations above aside, do the authors
ave an opinion regarding the outcome of endovascular failure
fter reviewing the records. Do patients who fail endovascular iliac
ntervention present with acute limb ischemia?
Dr Rachel C. Danczyk. Thank you for your thought-provok-
ng comments and interesting question. First, we know that 20% of
hose patients presenting with claudication progress to critical limb
schemia (CLI) after endovascular failure. The number of patients
ith acute limb ischemia, specifically, in this group is quite small,
ith only eight patients presenting with acute ischemia after fail-
re. The majority of patients who presented with progression to
LI experienced rest pain, followed by ulcers, and finally with
cute ischemia.
Dr Nehler. Second, the number of patients with concomitant
istal bypasses was not given in the results. Does having a distal
evascularization dependent on revascularized inflow affect the ap-
roach to endovascular therapy in the aortoiliac segment proximally?
Dr Danczyk. At the time of initial percutaneous transluminal
ngioplasty and stenting (PTAS), 44 patients underwent lower
xtremity bypass operations. In general, the best operative ap-
roach is applied to each patient and if inflow can be established
ith aortoiliac artery stenting, even if a distal bypass is anticipated,
hen an endovascular approach to aortoiliac occlusive disease
AIOD) is pursued. Therefore, having a distal bypass dependent
n revascularized inflow does not affect the approach to endovas-
ular therapy in the aortoiliac artery segment.
Dr Nehler. Third, what if any role does surveillance have in
hese procedures?
DrDanczyk.We do not currently have a surveillance protocol
or iliac stent patients like we do for those with bypass grafts. In
eneral, patients are followed with attention paid to clinical symp-
oms and ankle-brachial indexes (ABIs). Since iliac artery stents are
ot intervened upon prophylactically, we do not utilize a surveil-
ance protocol.
Dr Nehler. The number of patients with concomitant distal
ypasses was not given in the results. Does having a distal revascu-
arization dependent on revascularized inflow affect the approach
o endovascular therapy in the aortoiliac segment proximally?
Dr Danczyk. At the time of initial PTAS, 44 patients under-
ent lower extremity bypass operations. In general, the best oper-
tive approach is applied to each patient and if inflow can be
stablished with aortoiliac artery stenting, even if a distal bypass is
nticipated, then an endovascular approach to AIOD is pursued.
herefore, having a distal bypass dependent on revascularized
nflow does not affect the approach to endovascular therapy in the
ortoiliac artery segment.
Dr Nehler. What if any role does surveillance have in these
rocedures?
DrDanczyk.We do not currently have a surveillance protocol
or iliac stent patients like we do for those with bypass grafts. In
eneral, patients are followed with attention paid to clinical symp-
oms and ABIs. Since iliac artery stents are not intervened upon
rophylactically, we do not utilize a surveillance protocol.
